The global market for treatments for neurodegenerative disorders will exceed $20 billion before the end of the decade, according to a new report.
The Food and Drug Administration has approved a supplemental new drug application for an opioid analgesic to treat diabetes-related pain.
The Food and Drug Administration has approved Lupin Pharmaceuticals' generic version of a drug used to treat pain and seizure disorders.
A Johnson & Johnson subsidiary has sent a regulatory application to the Food and Drug Administration seeking approval for one of its drugs in treating diabetes-related pain.
Nipro Diagnostics and NeuroMetrix have teamed up to market a point-of-care test that is designed to evaluate such systemic neuropathies as diabetic peripheral neuropathy.
Drug maker Pfizer is suspending some clinical studies of a biotech drug for treating pain...